Several small-molecule targeted therapies that block the FGF/FGFR signaling axis by tyrosine kinase inhibitors (TKIs) have been studied in CCA with FGFR alterations [20] and only CCA with FGFR2 fusion can benefit from FGFR inhibitors. This evidence concerns the gene FGFR2 and cholangiocarcinoma.